Claims
- 1. A substantially purified antibody comprising a variable heavy (VH) complementarity determining region (CDR)1 having an amino acid sequence of SEQ ID NO:49 or 73, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
- 2. A substantially purified antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50 or 74, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
- 3. A substantially purified antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:51 or 75, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
- 4. A substantially purified antibody comprising a variable light (VL) CDR1 having an amino acid sequence of SEQ ID NO:52 or 76, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
- 5. A substantially purified antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53 or 77 antibody immunospecifically binds to a TANGO 268 antigen.
- 6. A substantially purified antibody comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54 or 78, wherein said antibody immunospecifically binds to a TANGO 268 antigen.
- 7. The antibody of claim 1 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62, 68 or 74.
- 8. The antibody of claim 1 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63, 69 or 75.
- 9. The antibody of claim 1 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:50, 56, 62, 68 or 74 and a VH CDR3 having an amino acid sequence of SEQ ID NO:51, 57, 63, 69 or 75.
- 10. The antibody of claim 1 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.
- 11. The antibody of claim 1 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.
- 12. The antibody of claim 1 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.
- 13. The antibody of claim 1 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.
- 14. The antibody of claim 7, 8 or 9 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.
- 15. The antibody of claim 7, 8 or 9 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.
- 16. The antibody of claim 7, 8 or 9 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO: 54, 60, 66, 72 or 78.
- 17. The antibody of claim 7 or 8 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.
- 18. The antibody of claim 9 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.
- 19. The antibody of claim 2 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:50, 56, 62, 68 or 75.
- 20. The antibody of claim 2 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.
- 21. The antibody of claim 2 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.
- 22. The antibody of claim 2 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 73.
- 23. The antibody of claim 2 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.
- 24. The antibody of claim 19 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO: 54, 60, 66, 72 or 78.
- 25. The antibody of claim 3 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76.
- 26. The antibody of claim 3 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77.
- 27. The antibody of claim 3 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.
- 28. The antibody of claim 3 further comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:52, 58, 64, 70 or 76, a VL CDR2 having an amino acid sequence of SEQ ID NO:53, 59, 65, 71 or 77, and a VL CDR3 having an amino acid sequence of SEQ ID NO:54, 60, 66, 72 or 78.
- 29. A Fab fragment of a mouse monoclonal antibody produced by the mouse hybridoma cell line 9012.2, 1P10.2, 8M14.3, 9E18.2 or 744.6 deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.
- 30. An antibody that competes for binding to a TANGO 268 antigen with the scFv clone A4, A9, A10 or C3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, patent deposit Number PTA-2443, patent deposit Number PTA-2444, or patent deposit Number PTA-2445.
- 31. An antibody that competes for binding to a TANGO 268 antigen with the mouse monoclonal antibody produced by the mouse hybridoma cell line 9012.2, 1P10.2, 8M14.3, 9E18.2 or 744.6 deposited with the ATCC® as patent deposit Number PTA-1746, patent deposit Number PTA-1747, patent deposit Number PTA-1748, patent deposit Number PTA-1749 or patent deposit Number PTA-1750.
- 32. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is a monoclonal antibody.
- 33. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is a hum an antibody.
- 34. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is a humanized antibody.
- 35. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is a Fab fragment.
- 36. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, 28, 30 or 31, wherein the antibody is an scFv.
- 37. The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, or 28-31, wherein the antibody is conjugated to a therapeutic or drug moiety.
- 38 The antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, or 28-31, wherein the antibody is conjugated to a detectable substance.
- 39. A pharmaceutical composition comprising an antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, or 28-31, and a pharmaceutically acceptable carrier.
- 40. A pharmaceutical composition comprising an antibody as in claim 37, and a pharmaceutically acceptable carrier.
- 41. A kit comprising an antibody as in any one of claims 1-6, 9, 13, 18, 23, 24, or 28-31 and instructions for use, in one or more containers.
- 42. A kit comprising an antibody as in claim 38 and instructions for use, in one or more containers.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. application Ser. No. 09/610,118, filed Jun. 30, 2000, which is a continuation-in-part of U.S. application Ser. No. 09/503,387, filed Feb. 14, 2000, which is a continuation-in-part of U.S. application Ser. No. 09/454,824, filed Dec. 6, 1999, which is a continuation-in-part of U.S. application Ser. No. 09/345,068, filed Jun. 30, 1999, the entire contents of each of which is incorporated herein by reference its entirety.
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
09610118 |
Jun 2000 |
US |
Child |
09829495 |
Apr 2001 |
US |
Parent |
09503387 |
Feb 2000 |
US |
Child |
09610118 |
Jun 2000 |
US |
Parent |
09454824 |
Dec 1999 |
US |
Child |
09503387 |
Feb 2000 |
US |
Parent |
09345068 |
Jun 1999 |
US |
Child |
09454824 |
Dec 1999 |
US |